Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model

por Despiegel, Nicolas, Kuehne, Felicitas, Martin, Monique, Shelbaya, Ahmed
Publicado 2012

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

por Yang, Jingyan, Liu, Rongzhe, Ektare, Varun, Stephens, Jennifer, Shelbaya, Ahmed
Publicado 2021

Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis

por Johnson, Courtney, Stephens, Jennifer, Walker, Christopher, Cappelleri, Joseph C, Shelbaya, Ahmed
Publicado 2020

Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study

por Yeh, Yu-Chen, Cappelleri, Joseph C., Marston, Xiaocong L., Shelbaya, Ahmed
Publicado 2021

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data

por Solem, Caitlyn T, Shelbaya, Ahmed, Wan, Yin, Deshpande, Chinmay G, Alvir, Jose, Pappadopulos, Elizabeth
Publicado 2016

The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis

por Shelbaya, Ahmed, Solem, Caitlyn T, Walker, Chris, Wan, Yin, Johnson, Courtney, Cappelleri, Joseph C
Publicado 2018

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

por Patel, Dipen, Shelbaya, Ahmed, Cheung, Raymond, Aggarwal, Jyoti, Park, Sang Hee, Coindreau, Javier
Publicado 2019

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians

por Yang, Jingyan, Blinzler, Kelly, Lankin, Joshua, Vijayakumar, Sapna, Maculaitis, Martine C., Shelbaya, Ahmed
Publicado 2021

Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States

por Yang, Jingyan, Carioto, Jennifer, Pyenson, Bruce, Smith, Rebecca, Jacobson, Nathaniel, Pittinger, Sean, Shelbaya, Ahmed
Publicado 2021

Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezo...

por Stephens, Jennifer M, Gao, Xin, Patel, Dipen A, Verheggen, Bram G, Shelbaya, Ahmed, Haider, Seema
Publicado 2013

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inf...

por Abraham, Bincy, Eksteen, Bertus, Nedd, Khan, Kale, Hrishikesh, Patel, Dipen, Stephens, Jennifer, Shelbaya, Ahmed, Chambers, Richard, Soonasra, Arif
Publicado 2022

Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score–Matched Analysis

por Solomkin, Joseph, Mullins, C. Daniel, Quintana, Alvaro, Eckmann, Christian, Shelbaya, Ahmed, Ernst, Frank R., Krukas, Michelle R., Reisman, Arlene
Publicado 2016